Biomimetic Artificial Cells for Targeted Immunological Tolerance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive therapies for transplant patients require lifelong administration, leading to significant side effects and increased vulnerability to infections, autoimmunity, heart disease, diabetes, and cancer, as they suppress the entire immune system rather than selectively inducing immunological tolerance.
Innovation Solution
Development of biomimetic artificial cells that mimic native immune cells, specifically activating regulatory T-cells through soluble and surface-bound factors, such as CCL22 and TGF-β, to induce targeted immunological tolerance without systemic immunosuppression, using biodegradable microparticles with controlled release mechanisms to present a biomimetic surface pattern that stimulates T-regulatory cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lifelong immunosuppressive drugs are administered to prevent rejection, then transplant survival is improved, but side effects and vulnerability to infections/autoimmunity increase
Solution Approach 1:
The invention segments the immune system into specific target cells (regulatory T-cells) rather than suppressing the entire immune system. The artificial presenting cells are segmented to present specific antigens and deliver specific signals (co-stimulatory molecules, cytokines) to selectively activate only the desired immunosuppressive pathway while leaving other immune functions intact.
Solution Approach 2:
The artificial presenting cells serve as an intermediary between the transplanted tissue and the patient's immune system. These engineered cells mediate the interaction by presenting donor antigens in a controlled manner and delivering specific signals that induce regulatory T-cell activation, thereby preventing direct harmful interactions between immune cells and graft while avoiding systemic immunosuppression.
2Reliability
If systemic immunosuppression is used to prevent rejection, then graft acceptance is improved, but immune competence deteriorates
Solution Approach 1:
The invention applies local quality by creating a localized immunosuppressive effect at the site of the artificial presenting cells rather than systemic suppression. The engineered cells are designed to interact specifically with regulatory T-cells in the local microenvironment, inducing immunotolerance locally while allowing the rest of the immune system to maintain full competence and respond to pathogens and tumors.
Solution Approach 2:
The invention changes the parameters of immune cell interaction by modifying the artificial presenting cells to express specific combinations of antigens, co-stimulatory molecules, and cytokines at controlled levels. This precise parameter control allows induction of immunotolerance through specific signaling pathways while preserving other immune functions that depend on different parameters.
3Duration of action of stationary object
If immunosuppressive drugs are administered continuously, then rejection is prevented, but toxicity and cancer risk increase
Solution Approach 1:
The artificial presenting cells are designed to be self-sufficient in inducing and maintaining immunotolerance. They continuously present donor antigens and deliver immunosuppressive signals autonomously without requiring continuous administration of external drugs. The engineered cells essentially serve themselves by maintaining the tolerogenic microenvironment indefinitely, providing long-term protection without the cumulative toxicity of lifelong pharmacological immunosuppression.
Solution Approach 2:
The invention performs preliminary action by establishing immunotolerance through activation of regulatory T-cells before potential rejection episodes occur. The artificial presenting cells are implanted or administered in advance to prime the immune system with donor-specific antigens in a tolerogenic context, creating a protective state that prevents future rejection without requiring continuous drug therapy.
Data Source
AI summary
The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.